LIFECORE BIOMEDICAL, INC. Environmental Analytics
Environmental and financial analysis dashboard for LIFECORE BIOMEDICAL, INC.. Industry: MANUFACTURING
Company Overview for LIFECORE BIOMEDICAL, INC.
Highlights
Showing data for FY2022
Operational Environmental Cost
$0.39m
Operational Environmental Cost Intensity
0.37%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$-7.47m
Decoupling Rate (2020-2022)
49%
Adjusted EBITDA
$12m
Adjusted EBITDA Margin
11%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| -78.69% | -92.75% | 17.74% | ||
| 0.79% | 0.49% | 0.06% | 0.06% | |
| -66.68% | -73.06% | 9.43% | ||
| 0.65% | 0.64% | 0.31% | 0.27% | |
| $8m | $2m | $0m | $0m | |
| -73.25% | -81.64% | 10.86% | ||
| 1.44% | 1.13% | 0.37% | 0.33% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
11%
Adjusted EBIT Margin
-5.06%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$544m | $186m | $103m | $128m | |
| -65.86% | -44.42% | 24.20% | ||
N/A | $188m | $91m | $169m | |
| 0.00% | 100.98% | 88.46% | 132.12% | |
N/A | $-2m | $12m | $-41m | |
| 0.00% | -0.98% | 11.54% | -32.12% | |
N/A | $-38m | $-5m | $-58m | |
| 0.00% | -20.67% | -4.69% | -44.88% | |
| ENVIRONMENTAL COST DATA | ||||
$8m | $2m | $0m | $0m | |
| 1.44% | 1.13% | 0.37% | 0.33% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
N/A | $-4m | $12m | $-42m | |
| 0.00% | -2.11% | 11.17% | -32.45% | |
N/A | $-41m | $-5m | $-58m | |
| 0.00% | -21.81% | -5.06% | -45.21% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.06%
Scope 2 (% of Sales)
0.31%
Operational Environmental Cost Intensity
0.37%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
LIFECORE BIOMEDICAL, INC. | US | $0m | 0.37% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022